Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Show More...
-
Website http://www.nektar.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.72 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.4 -1.19 -1.5 -1.4 -0.42 -0.61 -1.1 -0.62 3.78 -2.52 -2.61 Dividends USD Payout Ratio % * Shares Mil 94.0 113.0 115.0 116.0 127.0 132.0 140.0 156.0 180.0 175.0 176.0 Book Value Per Share * USD 0.96 2.02 0.41 -0.43 0.36 0.29 -0.44 0.53 10.32 8.43 7.28 Free Cash Flow Per Share * USD -0.93 -0.64 -1.22 -1.26 -0.58 -0.27 -1.07 -0.41 4.29 -2.0 Return on Assets % -6.92 -23.76 -31.12 -34.75 -12.31 -17.2 -28.67 -17.94 51.25 -21.35 -22.68 Financial Leverage (Average) 5.75 3.07 10.59 12.16 78.09 6.46 5.79 1.25 1.41 1.46 Return on Equity % -39.31 -92.89 -140.39 -379.68 -324.73 -109.91 75.47 -28.22 -31.38 Return on Invested Capital % -9.62 -26.69 -76.54 -27.73 -43.87 -22.44 59.76 -21.84 -24.7 Interest Coverage -2.32 -12.01 -4.11 -2.92 -0.4 -1.07 -2.62 -1.35 16.96 -8.49 -8.52 Current Ratio 5.52 1.0 4.01 2.63 4.5 5.72 5.9 5.82 17.53 4.02 3.79 Quick Ratio 5.32 0.89 3.6 2.44 3.77 5.37 5.6 5.36 16.81 3.85 3.68 Debt/Equity 2.56 0.07 2.91 3.55 37.83 2.79 2.79 0.14 0.1 0.11